$SAVA
CASSAVA SCIENCES INC

2019 Q1 Form 10-K Financial Statement

#000106953019000019 Filed on March 29, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $880.0K $750.0K $3.690M
YoY Change -20.0% -14.77% -14.78%
% of Gross Profit
Research & Development $574.0K $0.00 $2.969M
YoY Change -46.25% -100.0% -61.01%
% of Gross Profit
Depreciation & Amortization $17.00K $0.00 $100.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.451M $750.0K $6.662M
YoY Change -33.04% -69.01% -44.25%
Operating Profit -$1.451M -$6.662M
YoY Change -33.04% -44.25%
Interest Expense $90.00K $70.00K $110.0K
YoY Change 800.0% 600.0% 175.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.360M -$680.0K -$6.560M
YoY Change -37.04% -71.9% -44.92%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.359M -$680.0K -$6.557M
YoY Change -37.08% -71.9% -44.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$79.25K -$39.47K -$614.2K
COMMON SHARES
Basic Shares Outstanding 17.22M 17.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.10M $19.80M $19.80M
YoY Change 78.5% 88.57% 88.57%
Cash & Equivalents $19.13M $19.81M $19.80M
Short-Term Investments
Other Short-Term Assets $140.0K $233.0K $200.0K
YoY Change -30.0% 26.63% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.27M $20.04M $20.00M
YoY Change 76.74% 87.94% 86.92%
LONG-TERM ASSETS
Property, Plant & Equipment $88.00K $87.00K $100.0K
YoY Change -12.0% -44.23% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $12.00K $0.00
YoY Change 0.0%
Total Long-Term Assets $258.0K $99.00K $100.0K
YoY Change 29.0% -41.07% 0.0%
TOTAL ASSETS
Total Short-Term Assets $19.27M $20.04M $20.00M
Total Long-Term Assets $258.0K $99.00K $100.0K
Total Assets $19.52M $20.14M $20.10M
YoY Change 75.88% 85.94% 86.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $495.0K $294.0K $300.0K
YoY Change 23.75% -30.66% -25.0%
Accrued Expenses $243.0K $156.0K $200.0K
YoY Change -19.0% -60.9% -71.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $902.0K $511.0K $500.0K
YoY Change 12.75% -54.86% -54.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $0.00 $0.00
YoY Change
Total Long-Term Liabilities $100.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $902.0K $511.0K $500.0K
Total Long-Term Liabilities $100.0K $0.00
Total Liabilities $970.0K $511.0K $500.0K
YoY Change 21.25% -54.86% -54.55%
SHAREHOLDERS EQUITY
Retained Earnings -$165.3M -$164.0M
YoY Change 4.17%
Common Stock $17.00K $17.00K
YoY Change 142.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.55M $19.63M $19.60M
YoY Change
Total Liabilities & Shareholders Equity $19.52M $20.14M $20.10M
YoY Change 75.88% 85.94% 86.11%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$1.359M -$680.0K -$6.557M
YoY Change -37.08% -71.9% -44.95%
Depreciation, Depletion And Amortization $17.00K $0.00 $100.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$604.0K -$600.0K -$4.770M
YoY Change -63.24% -57.14% -42.09%
INVESTING ACTIVITIES
Capital Expenditures $18.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$18.00K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $14.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -60.00K -100.0K 14.10M
YoY Change -103.16%
NET CHANGE
Cash From Operating Activities -604.0K -600.0K -4.770M
Cash From Investing Activities -18.00K 0.000 0.000
Cash From Financing Activities -60.00K -100.0K 14.10M
Net Change In Cash -682.0K -700.0K 9.328M
YoY Change -367.45% -50.0% -252.02%
FREE CASH FLOW
Cash From Operating Activities -$604.0K -$600.0K -$4.770M
Capital Expenditures $18.00K
Free Cash Flow -$622.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001069530
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17219300
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
11955662
CY2018 dei Entity Registrant Name
EntityRegistrantName
CASSAVA SCIENCES INC
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Trading Symbol
TradingSymbol
SAVA
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 sava Number Of Grants Awarded
NumberOfGrantsAwarded
2
CY2017 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1400000
CY2018 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
3000000
CY2018 sava Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
14098000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
424000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
294000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
399000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
800000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
900000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
167091000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183567000
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
19000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
36000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2496542
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11991175
CY2017Q4 us-gaap Assets
Assets
10831000
CY2018Q4 us-gaap Assets
Assets
20139000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
10663000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
20040000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16615000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10479000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19807000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6136000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9328000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6595509
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17219300
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6595509
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27500000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28800000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15600000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16500000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
200000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
100000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6400000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6500000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5300000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5700000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27500000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28800000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
69000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.82
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
309000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
61000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
49000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-248000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-172000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4334000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3693000
CY2018Q4 us-gaap Grants Receivable
GrantsReceivable
6700000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
129000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-130000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
372000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-243000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-26000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12000
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
38000
CY2018 us-gaap Interest And Other Income
InterestAndOtherIncome
105000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2017Q4 us-gaap Liabilities
Liabilities
1132000
CY2018Q4 us-gaap Liabilities
Liabilities
511000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10831000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20139000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1132000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
511000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2100000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
184000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
233000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
400000
CY2018Q4 us-gaap Net Rentable Area
NetRentableArea
6000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14098000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2101000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8237000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4770000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-11911000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-6557000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Operating Expenses
OperatingExpenses
11949000
CY2018 us-gaap Operating Expenses
OperatingExpenses
6662000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-11949000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-6662000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
194000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
99000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
95000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000
CY2017 us-gaap Other Noncash Income
OtherNoncashIncome
2000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
399000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14098000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
400000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.74
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7615000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2969000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157399000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163956000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.98
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2973000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2388000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.83
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.18
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.87
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0290
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.02
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.027
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1931288
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.63
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M22D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
314682
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
297500
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.73
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.43
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
19.63
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1931288
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2964973
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
14.14
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2982155
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2964973
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.74
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.14
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M19D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y22D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2964973
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.14
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y22D
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
18637000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
9699000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
19628000
CY2017 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1429
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1429
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2017 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
2954000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
2352000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4200000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4300000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4400000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
100000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
100000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;">&#xFEFF;</font> </p> <p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10300000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1300000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6537000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10682000

Files In Submission

Name View Source Status
0001069530-19-000019-index-headers.html Edgar Link pending
0001069530-19-000019-index.html Edgar Link pending
0001069530-19-000019.txt Edgar Link pending
0001069530-19-000019-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sava-20181231.xml Edgar Link completed
sava-20181231.xsd Edgar Link pending
sava-20181231x10k.htm Edgar Link pending
sava-20181231xex23_1.htm Edgar Link pending
sava-20181231xex31_1.htm Edgar Link pending
sava-20181231xex31_2.htm Edgar Link pending
sava-20181231xex32_1.htm Edgar Link pending
sava-20181231xex3_3.htm Edgar Link pending
sava-20181231xex3_4.htm Edgar Link pending
sava-20181231_cal.xml Edgar Link unprocessable
sava-20181231_def.xml Edgar Link unprocessable
sava-20181231_lab.xml Edgar Link unprocessable
sava-20181231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending